Sanford Bemidji Blackduck Clinic in Blackduck, MN - Family Medicine

Sanford Bemidji Blackduck Clinic is a primary clinic (Family Medicine) in Blackduck, Minnesota. The current practice location for Sanford Bemidji Blackduck Clinic is 81 1st Street Nw, Blackduck, Minnesota. For appointments, you can reach them via phone at (218) 835-4222. The mailing address for Sanford Bemidji Blackduck Clinic is 720 4th St N, Po Box 2010, Fargo, North Dakota and phone number is (218) 835-4222.

Sanford Bemidji Blackduck Clinic is licensed to practice in * (Not Available) (license number ) and its NPI number is 1831130921. This medical practice does not participate in medicare program and thus may not accept your medicare insurance. You may check if they accept your insurance at (218) 835-4222.

Contact Information

	Sanford Bemidji Blackduck Clinic
	81 1st Street Nw Blackduck MN 56630
	(218) 835-4222
	(218) 835-5837

Primary Care Clinic Profile

Full Name	Sanford Bemidji Blackduck Clinic
Speciality	Family Medicine
Location	81 1st Street Nw, Blackduck, Minnesota
Authorized Official Name and Position	Martha K Leclerc (VP)
Authorized Official Contact	7012346248
Accepts Medicare Insurance	This clinic does not participate in Medicare Program.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Sanford Bemidji Blackduck Clinic 720 4th St N Po Box 2010 Fargo ND 58122-0605 Ph: (218) 835-4222	Sanford Bemidji Blackduck Clinic 81 1st Street Nw Blackduck MN 56630 Ph: (218) 835-4222

NPI Details:

NPI Number	1831130921
Provider Enumeration Date	06/09/2006
Last Update Date	11/27/2023

Medical Identifiers

Medical identifiers for Sanford Bemidji Blackduck Clinic such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1831130921	NPI	-	NPPES
939721300	Medicaid	MN

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Q00000X	Family Medicine	(* (Not Available))	Primary

News Archive

Study uncovers changes to the brain during unconsciousness

Three new studies have uncovered the mechanism by which brain networks are degraded whilst a person is unconscious.

Daiichi Sankyo files NDA for development and marketing of Methylene Blue medicinal product in Japan

Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.

Potential target for the development of a drug to treat memory loss

A mind-altering mutation in mice results in an enhanced long-term memory, researchers report in the April 6, 2007 issue of the journal Cell, published by Cell Press.

Improving ACA's Insurance Coverage Provisions will lead to better care for patients

The American College of Physicians published a paper today in the Annals of Internal Medicine that examines ways to improve the Affordable Care Act.

UK's health performance: an interview with Prof. Murray, University of Washington

Rates of premature mortality in the UK have been falling steadily, but the pace of decline is not as fast as in many other high-income countries, such as Australia. In that sense, the UK lags behind.

Sanford Bemidji Blackduck Clinic - Primary Care in Blackduck, MN